Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Caladrius Biosciences Q1 EPS $(0.07) Beats $(0.10) Estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 63.16 percent increase over losses of $(0.19) per share

byBill Haddad

May 5, 2022

1 minute read

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 63.16 percent increase over losses of $(0.19) per share from the same period last year.